Lung Cancer: Novel Agents in First-Line Therapy

Results of important recent clinical studies of first-line EGFR TKI therapies, antibodies combined with chemotherapy, consolidation and up-front supportive care are creating the potential to change the paradigm for what constitutes appropriate first-line care for non–small cell lung cancer (NSCLC) patients. Medical professionals who work with lung cancer patients need to understand the results of these new studies, assess their implications for the management of NSCLC, and integrate this information into their practice of assessing, counseling and treating individual patients.

Novel Agents in the Treatment of Lung Cancer: New Approaches to First-Line Therapy is a monograph based of reviews on recent advances in first-line therapy for non-small cell lung cancer. The activity offers up to 3 AMA PRA Category 1 Credits™.

Lung Cancer: CASE STUDIES Assessing Novel Agents in First-Line Therapy is based on videotaped discussion of cases studies. The activity provides more in-depth information on this topic, featuring an overview by Thomas J. Lynch, Jr, MD and discussion of 4 cases by the same program faculty that developed the monograph. The activity offers up to 2 additional AMA PRA Category 1 Credits™.

Target Audience: This educational activity is intended for oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.

Faculty Listing:
Thomas J. Lynch, Jr., MD - Yale Cancer Center
Tracy T. Batchelor, MD - Massachusetts General Hospital Cancer Center
Tracey Evans, MD - Abramson Cancer Center
Panos Fidias, MD - Massachusetts General Hospital Center for Thoracic Cancers
Glenwood D. Goss, MD, FCPSA, FRCPC - Ottawa Hospital Cancer Centre
Nasser H. Hanna, MD - Indiana University School of Medicine
Daniel D. Karp, MD -The University of Texas MD Anderson Cancer Center
Natasha Leighl, MD, MMSc, FRCPC - Princess Margaret Hospital

Novel Agents in the Treatment of Lung Cancer: New Approaches to First-Line Therapy
Credit Hours	Credit Type
3.0	AMA PRA

 

Lung Cancer: CASE STUDIES Assessing Novel Agents in First-Line Therapy
Credit Hours	Credit Type
2.0	AMA PRA

 

[Back to top]

[Back to Activity Home]